Sandrine Marreaud
AuthID: R-00G-F9A
1
TITLE: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression Full Text
AUTHORS: Wildiers, Hans; Meyskens, Thomas; Marreaud, Sandrine; Dal Lago, Lissandra; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Meulemans, Bart; Sousa, Berta; Poncet, Coralie; Brain, Etienne;
PUBLISHED: 2022, SOURCE: BREAST, VOLUME: 64
AUTHORS: Wildiers, Hans; Meyskens, Thomas; Marreaud, Sandrine; Dal Lago, Lissandra; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Meulemans, Bart; Sousa, Berta; Poncet, Coralie; Brain, Etienne;
PUBLISHED: 2022, SOURCE: BREAST, VOLUME: 64
INDEXED IN: 
Scopus 
WOS
Scopus WOS2
TITLE: A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study) Full Text
AUTHORS: Pierre Fumoleau; Kevin M Koch; Etienne Brain; Francois Lokiec; Keyvan Rezai; Ahmad Awada; Larry Hayward; Gustavo Werutsky; Jan Bogaerts; Sandrine Marreaud; Fatima Cardoso;
PUBLISHED: 2014, SOURCE: BREAST, VOLUME: 23, ISSUE: 5
AUTHORS: Pierre Fumoleau; Kevin M Koch; Etienne Brain; Francois Lokiec; Keyvan Rezai; Ahmad Awada; Larry Hayward; Gustavo Werutsky; Jan Bogaerts; Sandrine Marreaud; Fatima Cardoso;
PUBLISHED: 2014, SOURCE: BREAST, VOLUME: 23, ISSUE: 5
